Key Highlights
- PharmaEssentia USA promotes Dr. Robert B. Geller to General Manager.
- Dr. Geller to focus on serving patients with myeloproliferative neoplasms (MPN).
- Notable contributions to BESREMi® medical strategy and expansion.
- Dr. Geller’s extensive experience in clinical trials and medical affairs.
- Significant roles at Aravive, Coherus Biosciences, and other prominent institutions.
Source: Business Wire
Notable Quote
- “Since joining PharmaEssentia, Dr. Robert Geller has clearly demonstrated his strategic mindset and strong leadership. Robert has made important contributions to our BESREMi® (ropeginterferon alfa-2b-njft) medical strategy, including our focus on expanding the use of BESREMi as a frontline polycythemia vera treatment, consistent with the product label and the NCCN guidelines implemented earlier this year.” — Dr. Ko-Chung Lin, Founder and CEO at PharmaEssentia
SoHC's Take
Dr. Robert B. Geller’s promotion to General Manager at PharmaEssentia USA underscores the company’s commitment to advancing treatment for myeloproliferative neoplasms. With his robust background in clinical trials and medical strategy, Dr. Geller is poised to drive significant progress in the utilization of BESREMi® for polycythemia vera, enhancing patient outcomes globally. His leadership and strategic vision are expected to further PharmaEssentia’s mission in delivering innovative biopharmaceutical solutions in hematology and oncology.
